TRPV1 protein inhibition effect of cyclic dipeptide and application of cyclic dipeptide
By using the ring (D-leucine-L-proline) dipeptide as a TRPV1 inhibitor, the problem of failure to effectively inhibit TRPV1 protein in the prior art was solved, and a significant improvement to the skin sensitivity was achieved, providing Effective soothing effects.
Patent Information
- Application Number
- CN202411297523.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-14
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-09-14
AI Technical Summary
The prior art has failed to effectively inhibit TRPV1 protein, resulting in skin sensitivity such as dry itch and tingling, and lacks clear soothing and cosmetic raw materials.
The ring (D-leucine-L-proline) dipeptide is used as a TRPV1 protein inhibitor, and it is used as an effective additive for drugs or skin topical agents to improve the sensitive state of the skin.
It significantly inhibits the content of TRPV1 protein, effectively reduces skin tingling, itching and redness, improves the sensitive state of the skin, and provides a soothing skin care effect.
Smart Images

Figure BDA0005047407510000041 
Figure BDA0005047407510000111 
Figure BDA0005047407510000121
Abstract
Description
Technical Field
[0001] The present invention belongs to the application of cyclic dipeptides, and specifically relates to a cyclic dipeptide with TRPV1 protein inhibitory effect, the structure of which is a cyclic (D-leucine-L-proline) dipeptide, which can prevent Ca 2+ The neurologically sensitive skin discomfort caused by inward flow can be used as an effective additive to prepare medicines or skin topical preparations to help improve skin sensitivity such as dryness, itching and stinging, and soothe the skin. Background Art
[0002] Sensitive skin refers to a highly reactive state of the skin under physiological or pathological conditions, mainly occurring on the face, with subjective symptoms such as burning, stinging, itching and tightness, with or without objective signs such as erythema, capillary dilation and desquamation. With factors such as environmental pollution, excessive cleaning and life stress, the proportion of sensitive skin is increasing.
[0003] The skin barrier is the first line of defense for the skin. Damage or dysfunction of the skin barrier may make the skin more sensitive, resulting in an inflammatory reaction. Among the types of sensitive skin, in addition to the abnormality of the skin barrier function, there is usually another situation, that is, the occurrence of neural hyperreactivity. The surface of keratinocytes expresses some receptors that can sense temperature, pain, etc., such as transient receptor potential (TRP). TRP can be activated by different physical, chemical or thermal stimuli, which are also the inducing factors of sensitive skin. On the one hand, electrical signals are transmitted to the nerve center, resulting in symptoms such as tingling and itching. On the other hand, the calcium ion influx caused by the activation of TRPV1 can also cause neuroinflammation, eventually leading to symptoms such as redness of the skin and erythema. The causes of sensitive skin are very complex. The formation of sensitive skin has a clear correlation with the pain and itch receptor TRPV1. When stimulated by external stimuli, the skin will produce pain, burning and itching. Therefore, to repair the skin barrier, it is necessary to improve the discomfort of sensitive skin such as tingling and itching from the source, which can reduce erythema and inflammation and accelerate barrier repair. Therefore, the inhibitory effect of TRPV1 is also a key target for evaluating cosmetic raw materials with soothing effects. Whether it is possible to develop active ingredients with clear inhibitory effects of TRPV1 protein has become the core development direction of functional skin care products for sensitive skin.
[0004] At present, some literature and patents have reported the effects of some ingredients in this regard, mostly plants or plant combinations, such as green peel, gentian, artemisia annua, combination of cherimoya fruit extract and hydrolyzed algae extract, combination of camellia and purslane, combination of patchouli leaf extract and frangipani flower extract, and tetrandrin. In addition, there are some reports on related peptides in this regard. For example, Chinese patent application 202310756911.6 provides an anti-aging composition that significantly relieves TRPV1 stimulation caused by retinol and its derivatives. By adding palmitoyl tripeptide-8 and / or acetyl dipeptide-1 cetyl ester to skin care products containing retinol / derivatives, the expression of TRPV1 protein in epidermal keratinocytes can be significantly inhibited; Chinese patent application 202310040156.1 provides a soothing and anti-allergic combination peptide and its application, wherein the soothing and anti-allergic combination peptide includes palmitoyl tripeptide-8 and acetyl dipeptide-1 cetyl ester; Chinese patent application 202310661203.4 discloses that a polypeptide TAT-TRPV1-C has application potential in the preparation of drugs for treating symptoms such as itching mediated by TRPV1; Chinese patent application 202211261864.X discloses a synthetic peptide that has the effect of inhibiting TRPV1.
[0005] Cyclo(D-leucine-L-proline) dipeptide is a cyclic dipeptide. Zhu Jiansheng et al. isolated cyclo(D-leucine-L-proline) compounds from marine bacteria (Zhu Jiansheng, Study on Cyclodipeptides and Their Biological Activities in Marine Bacteria Pseudomonas putida [D], Jiangsu: Yangzhou University, 2013). The invention patent applied for by South China Agricultural University involves the application of a cyclo(D-leucine-L-proline) dipeptide and its plant antibacterial agent, wherein the application is as a plant antibacterial agent.
[0006] However, none of these documents studies or mentions the activity research of cyclic (D-leucine-L-proline) dipeptide in beauty and skin care.
[0007] The present invention unexpectedly discovered that cyclic (D-leucine-L-proline) dipeptide has an inhibitory effect on TRPV1 (transient receptor potential vanilloid 1 (TRPV1)) protein. In the study, it was found that cyclic (D-leucine-L-proline) dipeptide has an excellent effect of inhibiting the content of TRPV1 protein, thereby preventing Ca 2+ In addition, cyclic dipeptide can also be used as an effective additive to prepare medicines or skin topical preparations to help improve skin sensitivity such as dryness, itching, and stinging, and soothe the skin. Summary of the invention
[0008] In one aspect, the present invention relates to the use of a cyclic dipeptide for inhibiting TRPV1 protein, wherein the cyclic dipeptide is a cyclic (D-leucine-L-proline) dipeptide.
[0009] In a preferred embodiment, the cyclic dipeptide is used at a concentration of 2.5 ppm to 40 ppm. In a preferred embodiment, the cyclic dipeptide is used at a concentration of 5 ppm to 40 ppm, or 20 ppm to 40 ppm.
[0010] On the other hand, the present invention also relates to the use of a cyclic dipeptide in the preparation of a skin external preparation, a medicine and a health food having a TRPV1 protein inhibitory effect, wherein the cyclic dipeptide is a cyclic (D-leucine-L-proline) dipeptide.
[0011] In a preferred embodiment, the content of the cyclic dipeptide in the external skin preparation, medicine and health food is 0.0001-20% by weight, more preferably 0.01-5% by weight.
[0012] In a preferred embodiment, the skin external preparation is selected from the following forms: facial cream, lotion, gel, toner, essence, facial mask, eye cream, aerosol cleansing foam, spray, shower gel, or facial cleanser. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1 The blank control, negative control, and the results of TRPV1 immunofluorescence of Examples 4, 3, 7, 6, and 5 are shown, and the magnification is 20 times.
[0015] Figure 2 The results of TRPV1 immunofluorescence of Example 8 are shown, and the magnification is 20 times. DETAILED DESCRIPTION
[0016] Unless otherwise defined, all technical and scientific terms used herein have the same meanings as commonly understood by those of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or equivalent to those described herein can be used to implement or test the present invention, preferred methods and materials are described herein. For purposes of the present invention, the following terms are defined below.
[0017] As used herein, the term "about" refers to an amount, level, value, dimension, size, or amount that differs by up to 30%, 20%, or 10% compared to the amount, level, value, dimension, size, or amount of a reference product. Percentages used herein, unless otherwise indicated, are by weight.
[0018] Throughout the specification and claims, unless otherwise required, the following words "comprise" and variations "comprising" and "including" will be understood to imply the inclusion of a stated integer or step, or a group of integers or steps, but not the exclusion of any other integer or step, or other group of integers or steps.
[0019] The cyclic dipeptides described herein may optionally be in the form of finished product packaging. In one embodiment, the packaging is a container such as a plastic, metal or glass tube or jar containing the cyclic dipeptide. The product may additionally have packaging such as a plastic or cardboard box for storing the container. In one embodiment, the product comprises the cyclic dipeptide and has instructions for guiding the user to apply the cyclic dipeptide to the skin to treat signs of skin aging as discussed below. Such instructions may be printed on the container, a label insert, or any other packaging.
[0020] As used herein, "topical application" means applying or spreading directly onto the external skin, scalp, or hair, for example, using the hands or an application device such as a wipe, roller, or spray.
[0021] As used herein, "cosmetically acceptable" means that the ingredients described by the term are suitable for use in contact with tissue (eg, skin or hair) without undue toxicity, incompatibility, instability, irritation, allergic response, or the like.
[0022] The present invention is based on the following unexpected discovery: cyclo(D-leucine-L-proline) dipeptide has a significant inhibitory effect on TRPV1 protein, indicating its effect in improving skin sensitivity conditions such as stinging, itching and redness. At the same time, cyclo(L-leucine-L-proline) dipeptide was used as a comparative example, and it was found that it did not have this effect.
[0023] Cyclic dipeptide
[0024] The present invention provides a cyclic dipeptide component, the structure of which is cyclic (D-leucine-L-proline) dipeptide.
[0025] Table 1 shows the structural information of cyclo(D-Leucine-L-Proline) dipeptide.
[0026] Table 1
[0027]
[0028] In a specific embodiment, the composition of the present invention uses cyclo(D-leucine-L-proline) dipeptide provided by Donghua University.
[0029] Medicines, health foods or skin external preparations containing cyclic dipeptides
[0030] The cyclic dipeptide of the present invention can be used as an efficacy additive in medicines, health foods or external skin preparations.
[0031] In some embodiments, the drug is selected from the group consisting of tablets, capsules, emulsions, suspensions, powders, granules, solutions, and various pharmaceutical dosage forms known in the art. Different dosages are added according to different types of dosage forms.
[0032] Health food is also called functional food. It has the function of regulating human body functions, but is not for the purpose of treating diseases, and is suitable for consumption by specific groups of people. In some embodiments, the health food can be in powder form.
[0033] In some embodiments, the cyclic dipeptide can be used for the preparation of a skin topical agent. The skin topical agent is preferably a cosmetic composition, including but not limited to products in the form of cream, lotion, gel, toner, essence, mask, eye cream, aerosol (cleansing foam), spray, shower gel and facial cleanser.
[0034] The content of the cyclic dipeptide in the external preparation for skin is 0.001 to 20% by weight, preferably 0.005 to 10% by weight, more preferably 0.01 to 5% by weight.
[0035] The skin external preparation is a general concept for all ingredients usually used on the outside of the skin, for example, it can be a cosmetic composition. The cosmetic composition can be a basic cosmetic, a facial makeup cosmetic, a body cosmetic, a hair care cosmetic, etc., and there is no special restriction on its dosage form, which can be reasonably selected according to different purposes. The cosmetic composition also contains different media or matrix excipients allowed by the cosmetics level according to different dosage forms and purposes.
[0036] The skin external preparation is a general concept for all ingredients usually used on the outside of the skin, for example, it can be a cosmetic composition. The cosmetic composition can be a basic cosmetic, a facial makeup cosmetic, a body cosmetic, a hair care cosmetic, etc., and there is no special restriction on its dosage form, which can be reasonably selected according to different purposes. The cosmetic composition also contains different media or matrix excipients allowed by the cosmetics level according to different dosage forms and purposes.
[0037] The skin topical preparation comprising the cyclic dipeptide can be topically applied to human skin and / or hair. The skin topical preparation may also comprise a cosmetically acceptable topical carrier, which may be about 50% by weight to about 99.99% by weight of the skin topical preparation (e.g., about 80% by weight to about 99% by weight of the skin topical preparation). In a preferred embodiment of the present invention, the cosmetically acceptable topical carrier comprises water. The cosmetically acceptable topical carrier may comprise one or more selected from wetting agents, emollients, greases, moisturizers and similar substances. In one embodiment, the cosmetically acceptable topical carrier comprises a substrate such as a nonwoven fabric or a membrane material.
[0038] Skin topical agents can be prepared into a variety of product types, including but not limited to lotions, creams, gels, sticks, sprays, ointments, cleansing liquid lotions and solid soaps, shampoos and hair conditioners, hair fixatives, pastes, foams, powders, mousses, shaving creams, wipes, patches, hydrogels, film-forming products, facial masks and skin films, films and cosmetics such as foundation and mascara. These product types can contain several types of cosmetically acceptable topical carriers, including but not limited to solutions, suspensions, emulsions (e.g., microemulsions and nanoemulsions), gels, solids and liposomes.
[0039] Skin topical preparations containing cyclic dipeptides can be formulated as solutions. Solutions generally contain aqueous solvents or organic solvents (e.g., about 50% to about 99.99% or about 90% to about 99% of cosmetically acceptable aqueous solvents or organic solvents). Examples of suitable organic solvents include propylene glycol, polyethylene glycol, polypropylene glycol, glycerol, 1,2,4-butanetriol, sorbitol esters, 1,2,6-hexanetriol, ethanol, and mixtures thereof.
[0040] Skin topical preparations can be formulated into solutions containing emollients. Such skin topical preparations preferably contain from about 2% to about 50% of one or more emollients. As used herein, "emollient" refers to a substance used to prevent or alleviate dryness, for example, by preventing the loss of skin moisture through the skin. Examples of emollients include, but are not limited to, vegetable oils, mineral oils, aliphatic esters, etc.
[0041] Lotions can be prepared from such solutions.Lotions typically contain from about 1% to about 20% (e.g., from about 5% to about 10%) of one or more emollients and from about 50% to about 90% (e.g., from about 60% to about 80%) water.
[0042] Another type of product that can be formulated from a solution is a cream. Creams typically contain from about 5% to about 50% (e.g., from about 10% to about 20%) of one or more emollients and from about 45% to about 85% (e.g., from about 50% to about 75%) water.
[0043] Although it is preferred that the skin external preparation containing the cyclic dipeptide contains water, as an alternative, the skin external preparation may be anhydrous or an ointment containing no water but organic and / or silicone solvents, oils, lipids and waxes. The ointment may contain a simple base of animal or vegetable oils or semisolid hydrocarbons. The ointment may contain about 2% to about 10% of one or more emollients and about 0.1% to about 2% of one or more thickeners.
[0044] The topical agent for skin application can be formulated as an emulsion. If the topical carrier is an emulsion, about 1% to about 10% (e.g., about 2% to about 5%) of the topical carrier contains one or more emulsifiers. The emulsifier can be nonionic, anionic or cationic. Examples of suitable emulsifiers include those commonly identified as suitable emulsifiers in the field of personal care and cosmetic formulations.
[0045] Lotions and creams can be formulated as emulsions. Typically such lotions contain 0.5% to about 5% of one or more emulsifiers. Such creams typically contain about 1% to about 20% (e.g., about 5% to about 10%) of one or more emollients; about 20% to about 80% (e.g., 30% to about 70%) of water; and about 1% to about 10% (e.g., about 2% to about 5%) of one or more emulsifiers.
[0046] Oil-in-water and water-in-oil type single emulsion skin care preparations, such as lotions and creams, are well known in the cosmetics field and can be used in the present invention. Multiphase emulsion skin external preparations (such as water-in-oil-in-water type and oil-in-water-in-oil type) can also be used in the present invention. Generally, such single-phase emulsions or multiphase emulsions contain water, emollients and emulsifiers as their basic ingredients.
[0047] Skin topical preparations containing cyclic dipeptides can also be formulated into gels (e.g., aqueous gels, alcoholic gels, alcohol / water gels or oily gels using suitable gelling agents). Suitable gelling agents for aqueous gels and / or alcoholic gels include, but are not limited to, natural gums, acrylic acid and acrylate polymers and copolymers, and cellulose derivatives (e.g., hydroxymethylcellulose and hydroxypropylcellulose). Suitable gelling agents for oils (e.g., mineral oils) include, but are not limited to, hydrogenated butylene / ethylene / styrene copolymers and hydrogenated ethylene / propylene / styrene copolymers. Such gelling agents typically contain between about 0.1% and 5% by weight of such gelling agents.
[0048] The external preparation for skin application comprising the cyclic dipeptide may also be formulated as a solid preparation (eg, a wax-based stick, a bar soap, a powder, or a wipe containing a powder).
[0049] In addition to the above-mentioned components, the external preparation for skin which can be used in the present invention may contain various other oil-soluble substances and / or water-soluble substances at levels conventionally established in its technical field for use in external preparations for skin for use on skin and hair.
[0050] The skin external preparation of the present invention may contain additional components commonly found in skin care compositions, such as emollients, skin regulators, emulsifiers, preservatives, antioxidants, fragrances, chelating agents, etc., as long as they are physically and chemically compatible with other components in the skin external preparation and do not affect the effects of the cyclic dipeptide of the present invention.
[0051] In some embodiments of the skin external preparation of the present invention, one or more preservatives may be used. Suitable preservatives include p-hydroxyacetophenone, C1-C4 alkyl parahydroxybenzoate and phenoxyethanol. Based on the total weight of the composition, the amount of the preservative is about 0.5 to about 2 weight %, preferably about 0.5 to 1 weight %.
[0052] In one example of the skin external preparation of the present invention, one or more antioxidants can be used. Suitable antioxidants include butylated hydroxytoluene (BHT), ascorbyl palmitate (BHA), butylated hydroxyanisole, phenyl-α-naphthylamine, hydroquinone, propyl gallate, nordihydroguaiaretic acid, vitamin E or vitamin E derivatives, vitamin C and its derivatives, calcium pantothenate, green tea extract and mixed polyphenols, and mixtures of the above-mentioned substances. The antioxidant used is about 0.02 to 0.5 weight % of the total weight of the composition, and more preferably from about 0.002 to 0.1 weight % of the amount used.
[0053] In one example of the skin external preparation of the present invention, one or more emollients can be used to act as lubricants through their ability to remain on the skin surface or in the stratum corneum to reduce flaking and improve the appearance of the skin. Typical emollients include fatty esters, fatty alcohols, mineral oils, polyether silicone copolymers, and the like. Examples of suitable emollients include, but are not limited to, polypropylene glycol ("PPG")-15 stearyl ether, PPG-10 cetyl ether, Steareth-10, Oleth-8, PPG-4 lauryl ether, vitamin E acetate, lanolin, cetyl alcohol, cetearyl ethylhexanoate, cetearyl alcohol, glyceryl stearate, hydroxystearate octyl, dimethyl polysiloxane, and combinations thereof. Cetyl alcohol, cetearyl ethylhexanoate, cetearyl alcohol, glyceryl stearate, and combinations thereof are preferred. When used, the emollient is used in an amount ranging from about 0.1 to about 30% by weight, preferably about 1 to about 30% by weight, based on the total weight of the composition.
[0054] In one example of the skin external preparation of the present invention, one or more moisturizers can be used. Moisturizers are also called humectants, which help to improve the effect of emollients, reduce flaking, remove the scales of the composition and improve the touch of the skin. Polyols can be used as moisturizers, including but not limited to glycerol, polyalkylene glycols, alkylene polyols and derivatives thereof, including butylene glycol, propylene glycol, dipropylene glycol, polyglycerol, polyethylene glycol and derivatives thereof, sorbitol, hydroxypropyl sorbitol, hexylene glycol, 1,3-dibutylene glycol, 1,2,6-hexanetriol, ethoxylated glycerol, propoxylated glycerol, and combinations thereof. When used, the amount of moisturizer is about 0.1 to about 20% by weight, preferably about 1 to about 15% by weight, based on the total weight of the composition.
[0055] In an example of the skin external preparation of the present invention, one or more emulsifiers can be used. Emulsifiers can be used within the scope of effective stabilizing amount. Preferably, based on the total weight of the composition, the emulsifier is used in an amount of about 1.0 to about 10.0 weight %, more preferably about 3.0 to about 6.0 weight %. Any emulsifier compatible with the components in the composition can be used. Suitable emulsifiers include stearic acid, cetyl alcohol, glyceryl stearate, lecithin, stearyl alcohol, Steareth-2, Steareth-20, acrylic acid (ester) class / C10-30 alkyl alcohol acrylate cross-linked polymer, and combinations thereof.
[0056] In one example of the skin external preparation of the present invention, one or more pH regulators can be used. The pH regulator useful in the skin external preparation of the present invention includes tromethamine. When used, the amount of the pH regulator based on the total weight of the composition is about 0.1 to about 2 weight %, preferably about 0.1 to about 1 weight %.
[0057] In a specific embodiment of the present invention, the skin topical agent comprises acrylates / C10-30 alkyl acrylate crosspolymer, glycerin, p-hydroxyacetophenone, glyceryl stearate and lecithin, cetearyl alcohol, cetearyl ethylhexanoate, tromethamine or a combination thereof.
[0058] Example
[0059] The present invention is further described below in conjunction with specific examples. It is necessary to point out that the examples are only used to further illustrate the present invention and cannot be construed as limiting the scope of the present invention. Those skilled in the art can make some non-essential improvements and adjustments based on the content of the present invention described above. The test methods in the following examples that do not specify specific conditions are usually based on conventional conditions or the conditions recommended by the manufacturer. Unless otherwise stated, all percentages and parts are by weight.
[0060] Cyclic (L-leucine-L-proline) dipeptide (purity ≥ 98%), naturally extracted or chemically synthesized, provided by Donghua University.
[0061] Cyclic (D-leucine-L-proline) dipeptide (purity ≥ 98%), naturally extracted or chemically synthesized, provided by Donghua University.
[0062] Embodiment 1:
[0063] Cyclic (D-leucine-L-proline) dipeptide was accurately weighed and prepared with PBS phosphate buffer to a concentration of 400 ppm as the test stock solution.
[0064] Embodiment 2:
[0065] Cyclic (L-leucine-L-proline) dipeptide was accurately weighed and prepared with PBS phosphate buffer to a concentration of 400 ppm as the test stock solution.
[0066] Embodiment 3:
[0067] Example 1 was diluted with culture medium to prepare a concentration of 40 ppm as a test solution.
[0068] Embodiment 4:
[0069] Example 1 was diluted with culture medium to prepare a concentration of 20 ppm as a test solution.
[0070] Embodiment 5:
[0071] Example 1 was diluted with culture medium to prepare a concentration of 10 ppm as a test solution.
[0072] Embodiment 6:
[0073] Example 1 was diluted with culture medium to prepare a concentration of 5 ppm as a test solution.
[0074] Embodiment 7:
[0075] Example 1 was diluted with culture medium to prepare a concentration of 2.5 ppm as a test solution.
[0076] Embodiment 8:
[0077] Example 2 was diluted with culture medium to prepare a concentration of 4 ppm as a test solution.
[0078] Test Example 1: Protein content detection method based on capsaicin receptor (TRPV1) of keratinocytes
[0079] 1. Test principle:
[0080] Based on keratinocytes, the soothing effect of the test sample is evaluated by detecting the protein content of capsaicin receptor (TRPV1). TRPV1 is inhibited after the test substance acts, which can indicate that the test substance achieves the soothing effect by inhibiting TRPV1.
[0081] 2. Test materials:
[0082] Keratinocytes Ep21072702 (Boxi, Guangdong), KC2500 (Boxi, Guangdong), PBS (Solebao), MTT (Sigma), DMSO (Sigma), paraformaldehyde (Sinopharm), TRPV1 antibody (Abcam).
[0083] CO2 incubator (Thermo, 150I), clean bench (Suzhou Antai, SW-CJ-1F), inverted microscope (Olympus, CKX41), and fluorescence microscope (Leica, DM2500).
[0084] 3. Test system:
[0085] Table 2
[0086]
[0087] 4. Test method:
[0088] 1) Cell seeding: 1.8×10 5 Keratinocytes were seeded into 6-well plates at a seeding density of 100 cells / well and incubated overnight in an incubator (37° C., 5% CO 2 ).
[0089] 2) Drug administration: According to the test system in the above table, when the cell plating rate in the 6-well plate reaches 40% to 50%, group drug administration is carried out, and the dosage per well is 2 mL, and each group has 3 replicate wells. After drug administration, the 6-well plate is placed in an incubator (37°C, 5% CO2) for incubation for 24 hours.
[0090] 3) TRPV1 detection: The cells were fixed with 4% paraformaldehyde for 30 minutes, and then immunofluorescence detection of capsaicin receptor (TRPV1) was performed. The cells were photographed and observed under a microscope, and the images were collected and analyzed.
[0091] 4) Statistical analysis of results: GraphPad Prism was used for graphing, and the results were expressed as Mean ± SD. The t-test was used for statistical analysis for comparison between groups. P < 0.05 was considered to be significantly different, and P < 0.01 was considered to be extremely significantly different.
[0092] 5. Test results
[0093] Based on the test plan, TRPV1 detection was carried out according to the immunofluorescence operation steps.
[0094] 1) TRPV1 immunofluorescence results
[0095] Figure 1-2 The results of TRPV1 immunofluorescence are shown, where green fluorescence represents the content of the target protein "TRPV1", and the higher the fluorescence intensity, the higher the protein content.
[0096] The experimental results show that compared with the BC group, the green fluorescence intensity of the NC group increased, indicating that the stimulation conditions of this test were effective; compared with the NC group, the green fluorescence intensities of Examples 3, 4, 5, 6, and 7 were all weakened, indicating that the examples had an inhibitory effect on TRPV1 protein, but Example 8, as a comparative example, did not show a decrease in fluorescence, indicating that it was ineffective.
[0097] 2) TRPV1 protein content detection results
[0098] The following table shows the results of TRPV1 protein content detection:
[0099] Table 3
[0100]
[0101] Note: When the t-test method was used for statistical analysis, compared with the BC group, the significance was indicated by #, P-value < 0.05 was indicated by #, and P-value < 0.01 was indicated by ##; compared with the NC group, the significance was indicated by *, P-value < 0.05 was indicated by *, and P-value < 0.01 was indicated by **.
[0102] The experimental results show that compared with the BC group, the TRPV1 protein content of the NC group increased significantly, indicating that the stimulation conditions of this test are effective; compared with the NC group, Examples 3-7 can significantly reduce the TRPV1 protein content (p<0.01), and show a dose-dependency that increases with increasing concentration, indicating that the examples themselves have a very significant inhibitory effect on the TRPV1 protein. However, as a comparative example, Example 8 did not show a decrease in fluorescence, indicating that it is ineffective. This also shows that not all leucine and proline have the same effect when connected, and the present invention is limited to D-leucine-L-proline.
[0103] Application Examples
[0104] The cyclic dipeptide of the present invention can be used as an intermediate raw material or an effective additive for the preparation of medicines, health foods or skin external preparations, and the skin external preparations are preferably cosmetic compositions, including but not limited to products in the form of creams, lotions, gels, toners, essences, masks, eye creams, aerosols (cleansing bubbles), sprays, shower gels and facial cleansers. The weight percentage of the cyclic dipeptide in the skin external preparation can be 0.0001%-20% (w / w), preferably 0.001%-10% (w / w), more preferably 0.001%-5% (w / w), and most preferably 0.01%-5% (w / w).
[0105] The following are specific application examples of cyclo(D-leucine-L-proline) dipeptide in skin external preparations, and the formulations and preparation methods of these preparations. In the following tables, "-" means no addition.
[0106] Application Example 1: Preparation of facial cream
[0107]
[0108] Application Example 2: Preparation of Emulsion
[0109]
[0110] Application Example 3: Preparation of Gel
[0111]
[0112]
[0113] Application Example 4: Preparation of lotion
[0114]
[0115] Application Example 5: Preparation of Essence
[0116]
[0117]
[0118] Application Example 6: Preparation of facial mask
[0119]
[0120]
[0121] Application Example 7: Preparation of Eye Cream
[0122]
[0123] Application Example 8: Preparation of Aerosol (Cleaning Bubble)
[0124]
[0125]
[0126] Application Example 9: Preparation of Spray
[0127]
[0128] Application Example 10: Preparation of shower gel
[0129]
[0130]
[0131] Application Example 11: Preparation of facial cleanser
[0132]
[0133]
Claims
1. Application of cyclic dipeptide in inhibiting TRPV1 protein, wherein: The cyclic dipeptide is a cyclo(D-leucine-L-proline) dipeptide.
2. The use according to claim 1, characterized in that The cyclic dipeptide is used at a concentration of 2.5 ppm to 40 ppm.
3. The use according to claim 2, characterized in that The cyclic dipeptide is used at a concentration of 5 ppm to 40 ppm.
4. The use according to claim 3, characterized in that The cyclic dipeptide is used at a concentration of 20 ppm to 40 ppm.
5. Use of a cyclic dipeptide in the preparation of a skin external preparation, a medicine and a health food having a TRPV1 protein inhibitory effect, wherein the cyclic dipeptide is a cyclic (D-leucine-L-proline) dipeptide.
6. The use according to claim 5, characterized in that The content of the cyclic dipeptide in external skin preparations, medicines and health foods is 0.0001-20% by weight.
7. The use according to claim 6, characterized in that The content of the cyclic dipeptide in external skin preparations, medicines and health foods is 0.01-5% by weight.
8. The use according to claim 5, characterized in that The skin external preparation is selected from the following forms: facial cream, lotion, gel, toner, essence, facial mask, eye cream, aerosol cleansing foam, spray, shower gel, or facial cleanser.
Citation Information
Patent Citations
Soothing anti-allergy combined peptide and application thereof
CN116003510A
Novel TRPV1 inhibitory peptide and composition containing the same for preventing skin aging or improving wrinkles
JP2015515455A
Novel Peptide Having Anti-inflammation Activity and Uses Thereof
KR102291069B1
Novel SST4 selective agonists as non-opioid analgesics
US20250257098A1
Compounds comprising cyclized somatostatin receptor binding peptides
WO2006114324A1
Cited By
Milk-derived functional peptide LQPEVMGVSKVKE as well as preparation method and application thereof
CN122562888A
